Defeat for Erythropoietin in Infant Encephalopathy

(MedPage Today) -- Erythropoietin was no help for newborns with hypoxic-ischemic encephalopathy already undergoing therapeutic hypothermia in the phase III HEAL trial.
Combined death or neurodevelopmental impairment by 22-36 months of age was...

Source: MedPage Today Neurology - July 14, 2022 Category: Neurology Source Type: news